Page last updated: 2024-08-05 11:20:16

isoflavones

Any isoflavonoid with a 3-aryl-1-benzopyran-4-one (3-aryl-4H-chromen-4-one) skeleton and its substituted derivatives.

ChEBI ID: 38757

Members (11)

MemberDefinitionRole
3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,7-dihydroxy-2-methyl-1-benzopyran-4-one3-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-5,7-dihydroxy-2-methyl-1-benzopyran-4-one
4-methyl-2-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentanoic acid [3-(4-nitrophenyl)-4-oxo-1-benzopyran-7-yl] ester4-methyl-2-[[(2-methylpropan-2-yl)oxy-oxomethyl]amino]pentanoic acid [3-(4-nitrophenyl)-4-oxo-1-benzopyran-7-yl] ester
4',7,8-trihydroxyisoflavone8-Hydroxydaidzein
7-Acetoxy-2-methylisoflavone7-Acetoxy-2-methylisoflavone
7-Hydroxy-2-methylisoflavone7-Hydroxy-2-methylisoflavone
7-hydroxy-8-(4-morpholinylmethyl)-3-phenyl-1-benzopyran-4-one7-hydroxy-8-(4-morpholinylmethyl)-3-phenyl-1-benzopyran-4-one
8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-hydroxy-1-benzopyran-4-one8-(diethylaminomethyl)-3-(2,3-dihydro-1,4-benzodioxin-6-yl)-7-hydroxy-1-benzopyran-4-one
acetic acid (4-oxo-3-phenyl-1-benzopyran-7-yl) esteracetic acid (4-oxo-3-phenyl-1-benzopyran-7-yl) ester
ipriflavoneA member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.ipriflavone
isoflavoneA simplest member of the class of isoflavones that is 4H-chromen-4-one in which the hydrogen at position 3 is replaced by a phenyl group.isoflavone
lupiwighteoneLupiwighteone

Research

Studies (297)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-199020 (6.73)18.7374
1990's119 (40.07)18.2507
2000's59 (19.87)29.6817
2010's72 (24.24)24.3611
2020's27 (9.09)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials47 (13.06%)5.53%
Reviews31 (8.61%)6.00%
Case Studies4 (1.11%)4.05%
Observational0 (0.00%)0.25%
Other278 (77.22%)84.16%